Early detection of
melanoma can significantly improve the prognosis.
早期检测黑色素瘤可以显著改善预后。
The dermatologist specializes in diagnosing and treating skin conditions, including
melanoma.
这位皮肤科医生专门诊断和治疗皮肤病，包括黑色素瘤。
Sun exposure is one of the major risk factors for developing
melanoma.
阳光曝晒是导致黑色素瘤发展的主要风险因素之一。
Melanoma is a type of skin cancer that develops from the pigment-producing cells known as melanocytes.
黑色素瘤是一种皮肤癌，由产生色素的细胞——黑色素细胞发展而来。
The mole has irregular borders and multiple colors, which could be a sign of
melanoma.
这颗痣边界不规则且有多种颜色，这可能是黑色素瘤的征兆。
Genetic predisposition plays a significant role in the development of
melanoma.
遗传倾向在黑色素瘤的发展中起着重要作用。
The doctor recommended regular skin checks to monitor for signs of
melanoma.
医生建议定期进行皮肤检查以监测黑色素瘤的迹象。
Melanoma can spread rapidly if not treated early, making it a serious health concern.
如果不早期治疗，黑色素瘤会迅速扩散，成为严重的健康问题。
Public awareness campaigns aim to educate people about the risks and prevention of
melanoma.
公众意识运动旨在教育人们了解黑色素瘤的风险和预防措施。
The new drug has shown promising results in clinical trials for treating advanced
melanoma.
这种新药在治疗晚期黑色素瘤的临床试验中显示出有希望的结果。
The first six indications, including as a treatment for unresectable or metastatic melanoma after the failure of standard systemic therapy, have been included in the 2023 edition of the national reimbursement drug list.
前六个适应症，包括标准全身治疗失败后不可切除或转移性黑色素瘤的治疗，已被列入2023年版的国家报销药物清单。
Toripalimab is also the only anti-PD-1 monoclonal antibody included in the list for the treatment of melanoma.
托里帕利单抗也是唯一一种被列入黑色素瘤治疗名单的抗PD-1单克隆抗体。
Among them, the first approval in China for the melanoma indication took only five months from filing to approval, registering the fastest approval for an imported biologic in the country.
其中，黑色素瘤适应症的上市申请更创下了从申报到获批仅5个月的记录，成为目前在中国获批最快的进口生物制剂。
A total of six new drugs and indications, including those for patients suffering from melanoma, ankylosing spondylitis (a rheumatic immune disease), and non-small cell carcinoma, were approved in China last year.
去年，中国批准了六种新药和适应症，包括针对黑色素瘤、强直性脊柱炎（一种风湿免疫疾病）和非小细胞肺癌的药物。
Medical circles, as well as various social sectors, should also attach more importance to melanoma, a type of skin cancer, experts said.
The incidence and mortality rates for melanoma have increased in the country over the past few years.
Chen Yong, director of the Malignant Melanoma Diagnosis and Treatment Center, which is part of the Shanghai-based Fudan University Cancer Center, said that the two disease subtypes with the highest incidence among Chinese patients are different from those common in the western countries, and therefore, there have been inadequate international studies focusing on those subtypes.
Called Toripalimab, and designed for treating skin cancer melanoma, the Chinese treatment was conditionally approved by the National Medical Products Administration under priority review on Monday, about nine months after the company filed its new drug approval application.
According to the NMPA, the new anti-PD-1 medicine will provide an important treatment alternative for Chinese patients suffering from melanoma, as the disease's mortality rate is increasing, with approximately 20,000 new cases annually.
Clinical trial results showed that the new medicine has an objective response rate of 17.3 percent among patients with certain kinds of melanoma and who have failed previous systemic treatment.